Quanterix’s Simoa® technology drives advances in Alzheimer’s disease research presented at 2022 Clinical Trials On Alzheimer’s Disease (CTAD) conference
Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances ...
